Skip to main content
. 2011 Aug 24;118(17):4567–4576. doi: 10.1182/blood-2011-05-355594

Figure 4.

Figure 4

PFS and overall survival with bosutinib treatment. PFS (A) and overall survival (B) are shown for chronic phase imatinib-resistant or -intolerant patients treated with bosutinib (all-treated population) at a median follow-up of 24.2 months.